Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of hematology 2021-04, Vol.96 (4), p.E95-E98
Hauptverfasser:	Brown, Jennifer R., Walker, Sarah R., Heppler, Lisa N., Tyekucheva, Svitlana, Nelson, Erik A., Klitgaard, Josephine, Nicolais, Maria, Kroll, Yasmin, Xiang, Michael, Yeh, Jennifer E., Chaudhury, Mousumi, Giaccone, Zachary T., Fernandes, Stacey M., Jacobsen, Eric D., Fisher, David C., Freedman, Arnold S., Davids, Matthew S., Supko, Jeffrey G., Wu, Catherine, Frank, David A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Agents - administration & dosage Antineoplastic Agents - therapeutic use B-Lymphocytes - drug effects B-Lymphocytes - metabolism Cell Line, Tumor Chronic lymphocytic leukemia Dose-Response Relationship, Drug Drug Repositioning Drug Screening Assays, Antitumor Female Gene Expression Profiling Gene Expression Regulation, Leukemic - drug effects Hematology Humans Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Lymphatic leukemia Male Middle Aged Neoplasm Proteins - antagonists & inhibitors Neoplasm Proteins - biosynthesis Neoplasm Proteins - genetics Pharmacodynamics Progression-Free Survival Pyrimethamine Pyrimethamine - administration & dosage Pyrimethamine - pharmacology Pyrimethamine - therapeutic use Stat3 protein STAT3 Transcription Factor - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!